A GMP Protocol for the Manufacture of Tregs for Clinical Application

Alice O'Neil; Matthew Brook; Seetha Abdul-Wahab; Joanna Hester; Giovanna Lombardi; Fadi Issa

doi:10.1007/978-1-0716-2647-4_14

A GMP Protocol for the Manufacture of Tregs for Clinical Application

Alice O'Neil, Matthew Brook, Seetha Abdul-Wahab, Joanna Hester, Giovanna Lombardi, Fadi Issa

Peter Gorer Department of Immunobiology

Transplantation Research Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.
Transplantation Research Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK. fadi.issa@nds.ox.ac.uk.

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Infusion of regulatory T cells is a promising therapeutic strategy in organ transplantation to modulate the immune system, prevent rejection, minimize the need for pharmaceutical immunosuppression, and improve long-term transplant outcomes. Here we describe a GMP-compliant method we have used for the manufacture of ex vivo expanded autologous regulatory T cells for use in clinical trials. [Abstract copyright: © 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.]

Original language	English
Pages (from-to)	205-227
Number of pages	23
Journal	Methods in molecular biology (Clifton, N.J.)
Volume	2559
DOIs	https://doi.org/10.1007/978-1-0716-2647-4_14
Publication status	Published - 2023

Keywords

Regulatory T cells
Pharmaceutical Preparations
Tolerance
Immune Tolerance
Immunosuppression Therapy
Graft Rejection - prevention & control
Immunosuppression minimization
Treg
T-Lymphocytes, Regulatory
Transplantation
Organ Transplantation

Access to Document

10.1007/978-1-0716-2647-4_14

Cite this

@article{bc052b2f15d3485d88cec6462ec9c277,

title = "A GMP Protocol for the Manufacture of Tregs for Clinical Application",

abstract = "Infusion of regulatory T cells is a promising therapeutic strategy in organ transplantation to modulate the immune system, prevent rejection, minimize the need for pharmaceutical immunosuppression, and improve long-term transplant outcomes. Here we describe a GMP-compliant method we have used for the manufacture of ex vivo expanded autologous regulatory T cells for use in clinical trials. [Abstract copyright: {\textcopyright} 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.]",

keywords = "Regulatory T cells, Pharmaceutical Preparations, Tolerance, Immune Tolerance, Immunosuppression Therapy, Graft Rejection - prevention & control, Immunosuppression minimization, Treg, T-Lymphocytes, Regulatory, Transplantation, Organ Transplantation",

author = "Alice O'Neil and Matthew Brook and Seetha Abdul-Wahab and Joanna Hester and Giovanna Lombardi and Fadi Issa",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2023",

doi = "10.1007/978-1-0716-2647-4_14",

language = "English",

volume = "2559",

pages = "205--227",

journal = "Methods in molecular biology (Clifton, N.J.)",

issn = "1940-6029",

}

TY - JOUR

T1 - A GMP Protocol for the Manufacture of Tregs for Clinical Application

AU - O'Neil, Alice

AU - Brook, Matthew

AU - Abdul-Wahab, Seetha

AU - Hester, Joanna

AU - Lombardi, Giovanna

AU - Issa, Fadi

PY - 2023

Y1 - 2023

N2 - Infusion of regulatory T cells is a promising therapeutic strategy in organ transplantation to modulate the immune system, prevent rejection, minimize the need for pharmaceutical immunosuppression, and improve long-term transplant outcomes. Here we describe a GMP-compliant method we have used for the manufacture of ex vivo expanded autologous regulatory T cells for use in clinical trials. [Abstract copyright: © 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.]

AB - Infusion of regulatory T cells is a promising therapeutic strategy in organ transplantation to modulate the immune system, prevent rejection, minimize the need for pharmaceutical immunosuppression, and improve long-term transplant outcomes. Here we describe a GMP-compliant method we have used for the manufacture of ex vivo expanded autologous regulatory T cells for use in clinical trials. [Abstract copyright: © 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.]

KW - Regulatory T cells

KW - Pharmaceutical Preparations

KW - Tolerance

KW - Immune Tolerance

KW - Immunosuppression Therapy

KW - Graft Rejection - prevention & control

KW - Immunosuppression minimization

KW - Treg

KW - T-Lymphocytes, Regulatory

KW - Transplantation

KW - Organ Transplantation

UR - http://www.scopus.com/inward/record.url?scp=85139477011&partnerID=8YFLogxK

U2 - 10.1007/978-1-0716-2647-4_14

DO - 10.1007/978-1-0716-2647-4_14

M3 - Article

C2 - 36180635

SN - 1940-6029

VL - 2559

SP - 205

EP - 227

JO - Methods in molecular biology (Clifton, N.J.)

JF - Methods in molecular biology (Clifton, N.J.)

ER -

A GMP Protocol for the Manufacture of Tregs for Clinical Application

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this